[
  {
    "ts": "2026-02-12T23:17:31+00:00",
    "headline": "How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025",
    "summary": "On February 10, 2026, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full‑year 2025 sales of US$6.07 billion, alongside sharply lower net income despite double‑digit revenue growth. The company paired this with 2026 guidance targeting 8%–10% sales growth and earnings per share of US$2.90–US$3.05, underpinned by expanding TAVR and TMTT valve portfolios. We’ll now examine how Edwards’ confident 2026 sales and EPS guidance reshapes the earlier investment narrative around...",
    "url": "https://finance.yahoo.com/news/investors-reacting-edwards-lifesciences-ew-231731857.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9ec153c3-abe0-3744-b59a-576b02729224",
      "content": {
        "id": "9ec153c3-abe0-3744-b59a-576b02729224",
        "contentType": "STORY",
        "title": "How Investors Are Reacting To Edwards Lifesciences (EW) 2026 Guidance After Profit Squeeze In 2025",
        "description": "",
        "summary": "On February 10, 2026, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full‑year 2025 sales of US$6.07 billion, alongside sharply lower net income despite double‑digit revenue growth. The company paired this with 2026 guidance targeting 8%–10% sales growth and earnings per share of US$2.90–US$3.05, underpinned by expanding TAVR and TMTT valve portfolios. We’ll now examine how Edwards’ confident 2026 sales and EPS guidance reshapes the earlier investment narrative around...",
        "pubDate": "2026-02-12T23:17:31Z",
        "displayTime": "2026-02-12T23:17:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-edwards-lifesciences-ew-231731857.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-reacting-edwards-lifesciences-ew-231731857.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]